| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Wellness publication |
| Population | Men and women |
| Source | Fitt Insider |
| URL | insider.fitt.co/?p=30115 (opens in a new tab) |
Specific claim evaluated
The FDA recently relaxed safety warnings for testosterone therapy and menopausal hormone therapy.
Primary research supporting or contradicting the claim
The FDA requested testosterone label updates in June 2026 after review of TRAVERSE and other data (U.S. Food and Drug Administration, 2026b). TRAVERSE showed noninferiority for major adverse cardiac events but a higher incidence of atrial fibrillation, acute kidney injury and pulmonary embolism (Lincoff et al., 2023).
Corrected evidence-based interpretation
For testosterone, the FDA requested label revisions that were pending at the time of the article, and the class labeling continues to include monitoring requirements, including blood pressure. 'Relaxed' omits that new warnings were also added after TRAVERSE.
Rationale for grade
The article is a business trend summary and the statement is directionally correct for the requested prostate and age-related changes. It omits that the testosterone changes were requests rather than final labels and that blood pressure monitoring language was added. The brevity is appropriate for the outlet; the grade reflects the missing qualification.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - U.S. Food and Drug Administration. Testosterone information. Postmarket drug safety information for patients and providers. Updated June 2026.
Supporting excerpt: "FDA requested updates to testosterone prescribing information in June 2026"